Press Releases August 6, 2026 08:05 AM

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences to Present at Piper Sandler Virtual CNS Symposium

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
HRMY

Harmony Biosciences Holdings, Inc., a pharmaceutical company focused on innovative therapies for rare neurological diseases, announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on August 13, 2026. The event will be webcast on the company's investor webpage.

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
HRMY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harmony Biosciences is actively engaging with investors and industry stakeholders through a virtual symposium.
  • The company focuses on developing therapies for rare neurological diseases, a niche but important pharmaceutical sector.
  • The webcast availability enhances transparency and accessibility for investors and interested parties.

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
[email protected]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]


Risks

  • The announcement is informational and does not include new product developments or financial results, which may limit immediate investor interest.
  • As a pharmaceutical company dealing with rare diseases, regulatory and clinical trial uncertainties remain inherent risks.
  • Market reaction to such investor presentations can be muted if no substantive new information is provided.

More from Press Releases

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026 Twin Disc Announces First Quarter Results Nov 4, 2026 UniFirst Declares Increased Cash Dividends Oct 30, 2026